investors-2019-new

Why invest in Aspen?

We have a proud heritage dating back more than 160 years and we are committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products in more than 150 countries. Our commercial pharmaceutical focus is in the Regional Brands, Anaesthetics, Thrombosis, High Potency & Cytotoxic categories.

With a market capitalisation of approximately R117,9 billion as at 30 June 2018, Aspen is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and it ranks among the top 40 listed companies on this exchange.

The Group operates 25 manufacturing facilities across 17 sites and holds international manufacturing approvals from some of the most stringent global regulatory agencies. Our manufacturing capabilities are scalable to demand and cover a wide variety of product-types including injectables, oral solid dose, liquids, semi-solids, steriles, biologicals, active pharmaceutical ingredients and nutritionals.

QUICK FACTS

Market capitalisation

R117,9 billion*

*As at 30 June 2018

Manufacturing facilities

25

SITES ACROSS THE GROUP

17

NUMBER OF Continents

6

APPROXIMATE Employees

+10 000

INVESTMENT PROPOSITION

Please click on a title below left for more information.

Strong market position

Diversified geographies and product offering

Proven track record

Leverages on local knowledge and expertise

Centralised Group activities facilitate synergies and mitigate pricing pressures

Positive growth drivers

Responsible corporate citizen

Other considerations

Strong market position

Strong market position

One of the largest pharmaceutical companies in the southern hemisphere
Substantial presence in major developing markets such as Latin America, Russia, Eastern Europe, sub-Saharan Africa and South East Asia
Accredited manufacturing facilities that are scalable to demand
Vertical integration advantages for the manufacture of certain of Aspen’s leading global brands
The leading pharmaceutical company in South Africa
One of the top five pharmaceutical companies in Australia

Diversified geographies and product offering

Diversified geographies and product offering

Well positioned in both developing and developed territories with products distributed in more than 150 countries and an established presence in approximately 50 of these countries
Approximately 80% of revenues and EBITA are generated from territories outside of South Africa
A broad product portfolio including branded medicines, biologicals, generics, infant nutritionals and other consumer healthcare products
Targeted acquisitions of product portfolios in niche therapeutic areas which have a broad geographical footprint and which present value creation opportunities for the Group
Diverse manufacturing capabilities across 26 manufacturing facilities covering a wide variety of product types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals
Diversification of geopolitical and currency risk

Proven track record

Leverages on local knowledge and expertise

Centralised Group activities facilitate synergies and mitigate pricing pressures

Positive growth drivers

Positive growth drivers

Provider of high quality, affordable medicines and products to historically under-served markets
Exposure to faster growing developing markets
Expanding footprint in targeted strategic growth territories
Ongoing consolidation of production volumes and procurement efficiencies at strategic manufacturing sites will deliver competitive advantages to the Group
Capital investment in production technologies and capacities to harness synergies from recent acquisitions in the medium term
Strong cash generation enables reinvestment into the business

Responsible corporate citizen

Responsible corporate citizen

Committed to pursuing the Group’s strategic objectives in a responsible and sustainable manner
Operates on an established foundation of strong corporate governance
Active participant in the United Nations Global Compact (“UN Global Compact”) initiative, applying the 10 Principles
Participant in the annual Carbon Disclosure and Water Disclosure Projects
Focused investment for the development of our human capital and empowerment of future leaders
A constituent of the FTSE/JSE Responsible Investment Index

Other considerations

Other considerations

Aspen’s shares have good trading liquidity, with an average daily trading volume of approximately 1,3 million shares for the 2016 financial year
Aspen’s executive directors are founders and material shareholders of the Group, ensuring alignment of shareholders’ and executives’ interests
Aspen operates in the pharmaceutical industry which is considered to be defensive in nature